TABLE 1

Recombinant C. crescentus

ProteinNameSequenceReference in which construct was first describedMean (range) % HIV-1 inhibition
Live virus-infected TZM-bl cellsaLive virus-infected PBMCsb
Blank controlCc-controlNAc11110.1 (80.8–137.7)d100 (99.9–100)d
GriffithsinCc-griffithsinSLTHRKFGGSGGSPFSGLSSIAVRSGSYLDAIIIDGVHHGGSGGNLSPTFTFGSGEYISNMTIRSGDYIDNISFETNMGRRFGPYGGSGGSANTLSNVKVIQINGSAGDYLDSLDIYYEQY1261 (19.6–85.2)56.7 (25.4–100)
MicrovirinCc-microvirinMPNFSHTCSSINYDPDSTILSAECQARDGEWLPTELRLSDHIGNIDGELQFGDQNFQETCQDCHLEFGDGEQSVWLVCTCQTMDGEWKSTQILLDSQIDNNDSQLEIG1261.8 (11.9–82.4)56 (−7.9–100)
CyanovirinCc-cyanovirinLGKFSQTCYNSAIQGSVLTSTCERTNGGYNTSSIDLNSVIENVDGSLKWQGSNFIETCRNTQLAGSSELAAECKTRAQQFVSTKINLDDHIANIDGTLKYE1251.6 (21.6–87.6)71.6 (15.9–100)
Fuzeon, T-20Cc-FuzeonMYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFM1258.8 (29.3–78.9)62 (8.3–100)
T-1249Cc-T1249WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF1240 (4.9–54.2)27.6 (−30.9–100)
C52Cc-C52NHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI1250.7 (12.2–81.3)86.8 (46.5–100)
MIP-1αCc-MIP1αAPLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPSVIFLTKRGRQVCADPSEEWVQKYVSDLELSA1160.3 (23–83)69.2 (11.2–97.2)
CD4Cc-CD4GDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQ1155.5 (10.6–72.5)74.6 (18–97.5)
CD4 mimeticCc-CD4M33F23NLHFCQLRCKSLGLLGKCAGSFCACV1236.2 (16–74.3)26.9 (36.5–93.2)
BmKn2Cc-BmKn2FIGAIARLLSKIFe
α-1-antitrypsinCc-A1ATLEAIPCSIPPEFLFGKPFVFLMIEQNTKSPLFMG
ElafinCc-elafinAQEPVKGPVSTKPGSCPIILIRCAMLNPPNRCLKDTDCPGIKKCCEGSCGMACFVPQ
IndolicidinCc-indolicidinILPWKWPWWPWRR
GB Virus C E2 proteinCc-GBVCE2WDRGNVTLLCDCPNGPWVWVPAFCQAVGHerein64.9 (19.5–86.4)75.7 (27.2–87.9)
  • a The mean and range presented are a summary of data from HIV-1 strains 89.6, BaL, JR-FL, and pykJR-CSF.

  • b The mean and range presented are a summary of data from HIV-1 strains 89.6, JR-FL, and SF162.

  • cNA, not applicable.

  • d Data represent the mean (range) percent infection.

  • e —, data are presented elsewhere (13).